10-Q: Charlotte's Web Narrows Losses, Boosts Revenue 4.2%

Charlotte's Web Holdings, Inc. reported a significant reduction in net loss and improved gross profit for Q2 2025, driven by revenue growth and cost-cutting measures including the termination of its MLB partnership.

Summary

• Revenue for the three months ended June 30, 2025, increased by 4.2% to $12,806 thousand, up from $12,289 thousand in the prior year.
• Gross profit surged by 132.0% to $5,990 thousand for the quarter, compared to $2,582 thousand in Q2 2024, with gross margin improving to 46.8% from 21.0%.
• Net loss for the quarter significantly decreased to $(6,288) thousand, an improvement from $(11,057) thousand in the same period last year.
• Selling, general, and administrative (SG&A) expenses decreased by 31.7% to $10,062 thousand, primarily due to the termination of the MLB Promotional Rights Agreement and cost-cutting initiatives.
• Net cash used in operating activities for the six months ended June 30, 2025, decreased to $(6,786) thousand, a substantial improvement from $(11,883) thousand in the prior year period.
• The MLB Promotional Rights Agreement was terminated on May 13, 2025, waiving $18 million in future rights fees and resulting in a gain of $2,326 thousand.
• The company's collaboration with DeFloria received FDA clearance for a Phase 2 clinical trial for AJA001 Oral Solution, a botanical pharmaceutical candidate for autism spectrum disorder symptoms.
• New product launches include Charlotte's Web Stay Asleep Cannabinol (CBN) gummies, functional mushroom gummies, CBG Focus Gummies, and the Brightside low-dose THC hemp gummy collection.

Sentiment

Score: 6

Explanation: The company shows significant financial improvements in revenue growth, gross profit, and reduced losses and cash burn, driven by strategic cost-cutting and new product launches. However, it remains unprofitable and continues to consume cash, with some past investments (SBH option, Stanley Brothers loan) showing poor returns. The long-term outlook depends on successful execution of new strategies and favorable regulatory developments.

Positives

• Revenue increased by 4.2% for the three months ended June 30, 2025, reaching $12,806 thousand, indicating sales traction across an expanded product portfolio.
• Gross profit significantly improved by 132.0% to $5,990 thousand for the quarter, with gross margin more than doubling to 46.8%, largely due to the absence of a $3.8 million inventory provision from the prior year.
• Net loss decreased substantially to $(6,288) thousand for the quarter, compared to $(11,057) thousand in Q2 2024, reflecting improved operational efficiency.
• Selling, general, and administrative expenses decreased by 31.7% to $10,062 thousand, driven by the termination of the MLB Promotional Rights Agreement and successful cost-cutting measures.
• Net cash used in operating activities for the six months ended June 30, 2025, improved to $(6,786) thousand from $(11,883) thousand, demonstrating reduced cash burn.
• The termination of the MLB Promotional Rights Agreement resulted in a $2,326 thousand gain and eliminated $18 million in future rights fee obligations.
• FDA clearance for DeFloria's Phase 2 clinical trial for AJA001 Oral Solution represents a significant advancement in botanical drug development using proprietary hemp extract.
• Expansion into new product categories like CBN gummies and functional mushrooms leverages brand recognition and addresses broader wellness markets.

Negatives

• Despite improvements, the company continues to report a net loss of $(6,288) thousand for the quarter and $(12,500) thousand for the six months ended June 30, 2025.
• Cash and cash equivalents decreased to $15,268 thousand as of June 30, 2025, from $22,618 thousand at December 31, 2024, indicating continued cash consumption.
• A loss of $1,543 thousand was recognized from changes in the fair value of financial instruments for the quarter, primarily due to a $1,100 thousand loss in the DeFloria investment.
• The SBH Purchase Option, acquired for $8,000 thousand, was valued at nil as of June 30, 2025, as exercising the option is considered highly unlikely.
• A $1,000 thousand promissory note loaned to one of the Stanley Brothers has been fully reserved for as of December 31, 2024, indicating a potential unrecoverable loan.

Risks

• New state regulations regarding THC/CBD limits, age verification, testing, labeling, and packaging could impact the ability to sell certain products as currently formulated or packaged.
• The fair value determination of the investment in DeFloria and the debt interest rate conversion feature involves a high degree of subjectivity and judgment using unobservable inputs, leading to estimation uncertainty.
• Long-term liquidity depends on future operating performance, revenue growth, and expense management, which are affected by general economic conditions and industry regulatory changes beyond the company's control.
• The ability to raise funds through additional equity and/or debt securities is dependent on capital market conditions, investor sentiment, and the intended use of proceeds.

Future Outlook

Management is focused on reducing negative cash flows from operations in the near to mid-term. A reduction in overall selling, general, and administrative expenses is expected in 2025 due to actions taken in the second half of 2024 and additional projected reductions in the second half of 2025. This includes improvements in operating efficiency, cost savings from a more efficient e-commerce platform, and a data-driven reorganization of the B2B business and retail partnering strategies. Existing cash and cash equivalents are believed to provide sufficient liquidity for the next 12 months.

Management Comments

• The company has refreshed its mission to 'Unearth the Science of Nature to Revolutionize Wellness,' evolving its wellness offerings to strengthen core leadership in CBD and extend beyond to include a broader range of botanical-based wellness solutions.
• Expanding beyond CBD leverages the company's brand recognition, intellectual property, and partnerships, including an ongoing collaboration with DeFloria LLC for botanical drug development.
• The company continues to assess the business and financial impacts of new state regulations, including steps to address new product formulation and labeling requirements, as well as costs and potential revenue impacts.

Industry Context

The company operates in the evolving hemp-derived CBD and botanical-based wellness products industry, which is subject to varying state-level regulations. The strategic shift to include minor cannabinoids and functional mushrooms aligns with a broader trend in the wellness market seeking diverse natural health solutions. The collaboration with DeFloria for botanical drug development positions the company in the emerging pharmaceutical application of cannabinoids, a higher-value segment distinct from the consumer wellness market, potentially offering a long-term growth avenue.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or industry benchmarks with detailed results for a direct assessment against global standards. The company identifies itself as a 'market leader' in hemp extract wellness products but does not quantify this position relative to competitors.

Management Changes

Legal Proceedings

• No material pending legal proceedings are expected to have a material adverse effect on the company's results of operations or financial condition.

Related Party Transactions

• A secured promissory note of $1,000 thousand was loaned to one of the Stanley Brothers in November 2020, extended to November 13, 2029, and fully reserved for as of December 31, 2024.
• The SBH Purchase Option with Stanley Brothers USA, purchased for $8,000 thousand in 2021, was valued at nil as of June 30, 2025, as its exercise is considered highly unlikely.
• The company jointly formed DeFloria with AJNA BioSciences and British American Tobacco, contributing proprietary hemp intellectual property and clinical/consumer data.
• A supply agreement with DeFloria involves the company supplying raw material at cost, recognizing $641 thousand in revenue and cost of goods sold for the three and six months ended June 30, 2025.
• A Master Services Agreement with DeFloria compensates the company for certain services, recognizing $75 thousand (Q2 2025) and $150 thousand (six months) in revenue and cost of goods sold.
• Accounts receivable from DeFloria totaled $1,059 thousand as of June 30, 2025, up from $648 thousand at December 31, 2024.
• A note receivable from DeFloria for lab equipment sale had a remaining balance of $37 thousand as of June 30, 2025.
• A new promissory note of $750 thousand was loaned to DeFloria on July 15, 2025, due upon the later of December 31, 2026, or a $10 million financing event for DeFloria.
• A consulting agreement was entered into with Jared Stanley, a former executive and current Board member, for a bi-weekly fee of $6 thousand.

Stakeholder Impact

• Shareholders: Reduced net losses and improved operational efficiency may positively impact investor confidence, but continued cash burn and the write-off of the SBH Purchase Option and full reservation of a related party loan indicate ongoing risks and past investment losses.
• Employees: Workforce adjustments undertaken as part of cost-cutting measures may have impacted employee numbers, but improved operating efficiencies could lead to a more stable long-term environment.
• Customers: Expansion into new product categories (CBN, functional mushrooms, low-THC gummies) offers a broader range of wellness solutions.
• Partners: The termination of the MLB agreement frees up significant capital, while the ongoing collaboration with DeFloria and the new loan demonstrate continued commitment to botanical drug development.

Next Steps

• Proceed with the FDA Phase 2 clinical trial for AJA001 Oral Solution by DeFloria.
• Continue investment in R&D efforts to identify new product opportunities and advance hemp cannabinoid science.
• Capitalize on the rapidly emerging botanical-based wellness products industry by driving customer acquisition and retention.
• Accelerate retail expansion and expand product lines beyond hemp-based products where science and strategic vision support it.
• Implement further reductions in selling, general, and administrative expenses in the second half of 2025 through improved operating efficiency, e-commerce platform optimization, and B2B business reorganization.

Key Dates

Recommendation

While Charlotte's Web has demonstrated significant operational improvements, including reduced losses, improved gross margins, and decreased cash burn, the company remains unprofitable. Strategic moves like the MLB agreement termination and new product launches are positive, but the declining cash balance and the write-off of the SBH Purchase Option highlight ongoing financial challenges and past missteps. The investment in DeFloria's pharmaceutical development is a long-term play with inherent risks. A 'hold' recommendation is appropriate as the company shows signs of turning around, but the path to sustained profitability and positive cash flow in a complex regulatory environment is still uncertain, warranting a cautious approach rather than a strong buy or sell.

Keywords

CBD, Hemp, Wellness, Botanical, Cannabinoids, CBN, Charlotte's Web, DeFloria, SEC, 10-Q, Consumer Health, Pharmaceuticals, Dietary Supplements